Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage.

@article{Pickard2000PotentialRO,
  title={Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage.},
  author={J. D. Pickard and Peter J. Kirkpatrick and Torben Melsen and R B Andreasen and Leslie Gelling and Tim Fryer and Jessica Matthews and Pawan Singh Minhas and Penny J. Hutchinson and Divakara Menon and S.P.M.J. Downey and Ian Robert Kendall and Jeremy Clark and Todd A. Carpenter and Elizabeth Williams and Lennart K Persson},
  journal={Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis},
  year={2000},
  volume={11 Suppl 1},
  pages={
          S117-20
        }
}
Rebleeding following aneurysmal subarachnoid haemorrhage is a major factor contributing to unfavourable outcome. Antifibrinolytic agents reduce the rate of rebleeding but increase the risk of cerebral ischaemia and infarction and hence provide no overall benefit. To address the theoretical concern that recombinant activated factor VII (NovoSeven, Novo Nordisk A/S, Bagsvaerd, Denmark) might increase the risk of cerebral ischaemia while stabilizing the clot at the site of aneurysmal rupture, an… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 20 CITATIONS

Medical Management of Patients with Aneurysmal Subarachnoid Haemorrhage

  • Gabriel J E Rinkel
  • Medicine
  • International journal of stroke : official journal of the International Stroke Society
  • 2008